July 20, 2022 7:55am

Hold, watch, lighten positions and then sell into dramatic share pricing strength

Pre-open indications: 1 Positive Indication, 1 Negative Indication, 3 Sell into Strength and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.25% or (-78 points), S&P futures are DOWN -0.25% (-10 points) and NASDAQ futures are DOWN -0.15% (-18 points) early in the pre-open – so far,


U.S. stock futures are diving lower on Wednesday

European markets were higher mid-morning,

Asia-Pacific markets were ticking higher



Indexes are diving after rallying Tuesday, with the market resuming a bounce from last month’s lows, as traders bet on strong corporate earnings reports, and wagered – believe against these markets have found a bottom.

The Dow closed UP +752.10 points (+2.42%); the S&P closed UP +105.29 points (+2.75%) while the Nasdaq closed UP +353.10 points (+3.11%).

Possible indications: earnings calendar remains busy with Biogen (BIIB) and Abbott Labs (ABT) among the notable companies set to report before the bell.

Economic Data Docket: Mortgage demand fell 7% compared with the previous week, hitting the lowest level since 2000, according to the Mortgage Bankers Association’s seasonally adjusted index.


RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: a relief rally, riding the high upside and rebound. Pray through this upturn, as the sector’s pricing valuations regain momentum. Never forget the force of gravity in a dramatically ascendent market!” … https://www.regmedinvestors.com/articles/12523


Ebb and flow –

Q3/22 – 1 holiday, 4 negative and 8 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative indications:

Sage Therapeutics (SAGE) closed up +$1.72 to $35.90 after Monday’s -$1.07 with a negative -$1.90 or -5.29% pre-open indication,


Sell into Strength:

CRISPR Therapeutics (CRSP) closed up +$4.42 to $83.78 after Monday’s -$4.03 with a positive +$0.32 or +0.38% pre-open indication,

Verve Therapeutics (VERV) closed up +$5.98 to $32.29 after Monday’s +$2.60, Friday’s -$0.49 with a positive +$0.24 or +0.74% pre-open indication.

Beam Therapeutics (BEAM) closed up +$6.60 to $64.61 after Monday’s +$0.39 with a positive +$0.39 or +0.60% pre-open indication.


Positive Indications:

Global Blood Therapeutics (GBT) closed up +$0.19 to $34.97 after Monday’s -$1.21, Friday’s +$1.26 and Thursday’s -$0.60 with a positive +$0.59 or +1.69% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$0.01 with 300 shares traded after Monday’s flat at $5.00 with 1,319 shares traded, Friday’s -$1.00 to $5.00 with 10.658 shares traded, Thursday’s +$0.12 to $6.00 <52-week low of $1.21> and last Wednesday’s +$1.33 to $5.88 with 376 shares traded <3 mo. Average = 1,721 shares>

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities


The BOTTOM LINE: I try to keep it simple … and short!

BEWARE sector dramatic daily highs …

We are up, down, up and down – it gets tiring! Portfolios are wailing, not crying.

We always need a … villain and they are multiplying – low volume as “Earnings’ season is coming, investors NEED to focus on LPS (loss-per-share), collaboration revenues and cash positions i.e., runways”.

Upcoming earnings announcements: earnings as Alnylam Pharmaceuticals (ALNY) Q2 announcement on Thursday 7/28, Sage Therapeutics (SAGE) on Tuesday, 8/2 and AxoGen (AXGN) on Wednesday, 8/3.

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position while it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.